Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prognostic Value of KRAS Mutation Subtypes and PD-L1 Expression in Patients With Lung Adenocarcinoma.

Clinical lung cancer - 1 Jul 2021

Tao Luwei, Miao Ruoyu, Mekhail Tarek, Sun Jingxin, Meng Lingbin, Fang Cheng, Guan Jian, Jain Akriti, Du Yuan, Allen Amanda, Rzeszutko Brenda L, Socinski Mark A, Chang Chung-Che

Abstract excerpt

BACKGROUND: The prognostic value of different KRAS (Kirsten rat sarcoma viral oncogene) mutation subtypes and their association with programmed death ligand 1 (PD-L1) expression in lung adenocarcinoma (LADC) remain unclear. We examined the association of KRAS mutation subtypes with clinical outcomes and PD-L1 expression status. PATIENTS AND METHODS: Patients diagnosed with KRAS-mutated LADC were evaluated for...

Topics

Join the communities discussing this publication.

Adenocarcinoma of Lung
B7-H1 Antigen
Disease-Free Survival
Follow-Up Studies
Lung Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Neoplasm Staging

Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 32807653
DOI: 10.1016/j.cllc.2020.07.004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostic Value of KRAS Mutation Subtypes and PD-L1 Expression in Patients With Lung Adenocarcinoma.PMID 32807653Read ↗

Clinicopathological Characteristics and Prognostic Impact of KRAS Mutations in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Prognostic value of KRAS G12C in advanced non-small cell lung cancer with high PD-L1 expression treated with upfront immunotherapy: a systematic review and meta-analysis.Semantic proximity Read ↗

Effect of mutant variants of the KRAS gene on PD-L1 expression and on the immune microenvironment and association with clinical outcome in lung adenocarcinoma patients.Semantic proximity Read ↗

Prognostic value of KRAS G12V mutation in lung adenocarcinoma stratified by stages and radiological features.Semantic proximity Read ↗

Prognostic value of KRAS mutations, TP53 mutations and PD-L1 expression among lung adenocarcinomas treated with immunotherapy.Semantic proximity Read ↗

KRAS G12V mutation upregulates PD‐L1 expression via TGF‐β/EMT signaling pathway in human non‐small‐cell lung cancerSemantic proximity Read ↗

Brief Report: Not Created Equal: Survival Differences by KRAS Mutation Subtype in NSCLC Treated With ImmunotherapySemantic proximity Read ↗

Efficacy of first-line immunochemotherapy across KRAS mutation subtypes in advanced lung adenocarcinoma.Semantic proximity Read ↗

The Prognostic Effect of KRAS Mutations in Non-Small Cell Lung Carcinoma Revisited: A Norwegian Multicentre StudySemantic proximity Read ↗

Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer.Semantic proximity Read ↗

KRAS G12D mutation predicts lower TMB and drives immune suppression in lung adenocarcinoma.Semantic proximity Read ↗

Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.